Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma
BACKGROUND Prostate stem cell antigen (PSCA) is a recently identified glycosylphosphatidylinositol (GPI)‐anchored cell surface protein belonging to the Thy‐1/Ly‐6 family of cell surface antigens. Prior data in prostate cancers indicated that PSCA is directly regulated by androgens and PSCA expressio...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2005-12, Vol.65 (4), p.299-305 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 305 |
|---|---|
| container_issue | 4 |
| container_start_page | 299 |
| container_title | The Prostate |
| container_volume | 65 |
| creator | Zhigang, Zhao Wenlu, Shen |
| description | BACKGROUND
Prostate stem cell antigen (PSCA) is a recently identified glycosylphosphatidylinositol (GPI)‐anchored cell surface protein belonging to the Thy‐1/Ly‐6 family of cell surface antigens. Prior data in prostate cancers indicated that PSCA is directly regulated by androgens and PSCA expression increases with high‐tumor grade, advanced stage, extracapsular invasion, and androgen‐independent progression. The effect of complete androgen ablation (CAA) on tumor PSCA mRNA expression has not been elucidated. The purpose of the present study was to investigate the variations in the expression levels of PSCA mRNA before and after CAA, and further evaluate the clinically prognostic value of PSCA in human prostate carcinoma.
MATERIALS AND METHODS
PSCA in situ hybridization (ISH) was performed on the cancerous pretreatment biopsy or transurethral resection of prostate (TURP) tissue of 42 men with primarily organ‐confined prostate cancer before CAA, and on their tumor tissue from radical retropubic prostatectomy after CAA with bicalutamide and goserelin acetate for 3 months prior to undergoing radical prostatectomy. Tumor cytoplasmic staining of PSCA mRNA was evaluated by two independent pathologists and the differences of PSCA mRNA expression levels between the samples before and after CAA were analyzed using the Student's t‐test. Thirty‐six to forty months follow‐up studies after radical retropubic prostatectomy were performed and aimed at assessing the correlation of PSCA mRNA expression level with local recurrences or metastases from the cancer.
RESULTS
The percent of cells positive for PSCA mRNA by ISH labeling declined from 67.3% (0–89%) ± 9.4% before CAA to 33.8% (0–92%) ± 7.7% after CAA (P |
| doi_str_mv | 10.1002/pros.20290 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68700086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68700086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4240-ed524e935332680f702828f551dc06fc8ad59e165915b6709e55e78c57da6003</originalsourceid><addsrcrecordid>eNp90c1O3DAUBWCralWmlE0foMqmFVQKXDuxnSxHoaWV0DAaEEhsLI9zA27zVztR4e1xmIHZdeXNd3yvjwn5ROGYArCT3nX-mAHL4Q2ZUchlDJDyt2QGTEKc0kTukQ_e_wYIHNh7skcFUM7zdEZ80TV9jQNGui1dd4dtpNe1HmzXRn7se4feo4-mEYMOyg_YRAbrOvjBTvxweVnMj6JmtZhH-PAcmMK2je7HRre7qNHO2LZr9EfyrtK1x4PtuU-ufny_Kn7G5xdnv4r5eWxSlkKMJWcp5glPEiYyqCSwjGUV57Q0ICqT6ZLnSAXPKV8LCTlyjjIzXJZaACT75Ovm2rDB3xH9oBrrp9V1i93olchkqCMTAX7bQBNW9Q4r1TvbaPeoKKipYTW9QT03HPDn7a3jusFyR7eVBvBlC7Q3uq6cbo31OycTynjKg6Mb98_W-PifkWq5urh8GR5vMjb8w8NrRrs_SshEcnWzOFOL0-L2-na1VIvkCW-Fovw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68700086</pqid></control><display><type>article</type><title>Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zhigang, Zhao ; Wenlu, Shen</creator><creatorcontrib>Zhigang, Zhao ; Wenlu, Shen</creatorcontrib><description>BACKGROUND
Prostate stem cell antigen (PSCA) is a recently identified glycosylphosphatidylinositol (GPI)‐anchored cell surface protein belonging to the Thy‐1/Ly‐6 family of cell surface antigens. Prior data in prostate cancers indicated that PSCA is directly regulated by androgens and PSCA expression increases with high‐tumor grade, advanced stage, extracapsular invasion, and androgen‐independent progression. The effect of complete androgen ablation (CAA) on tumor PSCA mRNA expression has not been elucidated. The purpose of the present study was to investigate the variations in the expression levels of PSCA mRNA before and after CAA, and further evaluate the clinically prognostic value of PSCA in human prostate carcinoma.
MATERIALS AND METHODS
PSCA in situ hybridization (ISH) was performed on the cancerous pretreatment biopsy or transurethral resection of prostate (TURP) tissue of 42 men with primarily organ‐confined prostate cancer before CAA, and on their tumor tissue from radical retropubic prostatectomy after CAA with bicalutamide and goserelin acetate for 3 months prior to undergoing radical prostatectomy. Tumor cytoplasmic staining of PSCA mRNA was evaluated by two independent pathologists and the differences of PSCA mRNA expression levels between the samples before and after CAA were analyzed using the Student's t‐test. Thirty‐six to forty months follow‐up studies after radical retropubic prostatectomy were performed and aimed at assessing the correlation of PSCA mRNA expression level with local recurrences or metastases from the cancer.
RESULTS
The percent of cells positive for PSCA mRNA by ISH labeling declined from 67.3% (0–89%) ± 9.4% before CAA to 33.8% (0–92%) ± 7.7% after CAA (P < 0.001). Before CAA, 40 of 42 cases (95.2%) were positive for PSCA mRNA labeling, however, after CAA the percentage of positive reactivity of PSCA mRNA was decreased to 27 of 40 cases (67.5%), in which none was found with local recurrences or distant metastases after radical prostatectomy on follow‐up. This decline in PSCA mRNA labeling was dependent on the original tumor grade with Gleason score of ≤ 6: 19.3% ± 4.7%, Gleason score of 7: 38.8% ± 7.2%, and a Gleason score of ≥ 8: 73.4% ± 13.8% (P < 0.05, respectively). The rest 13 cases had the increased percentage of cells positive for PSCA mRNA after CAA, in which 3 cases were found with local recurrences and 4 cases with distant metastases from tumor on follow‐up.
CONCLUSIONS
Our data demonstrate that CAA for prostate cancer can suppress PSCA mRNA expression with a tumor grade dependence and the increased expression of PSCA mRNA after CAA may be a clinically adverse predictor for tumor recurrences or distant metastases. Prostate. © 2005 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.20290</identifier><identifier>PMID: 16015594</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Aged ; Aged, 80 and over ; Androgen Antagonists - therapeutic use ; Anilides - therapeutic use ; Antigens, Neoplasm ; Biological and medical sciences ; Biopsy ; complete androgen ablation (CAA) ; Follow-Up Studies ; GPI-Linked Proteins ; Gynecology. Andrology. Obstetrics ; Humans ; In Situ Hybridization ; Male ; Medical sciences ; Membrane Glycoproteins - antagonists & inhibitors ; Membrane Glycoproteins - biosynthesis ; Middle Aged ; Neoplasm Proteins - antagonists & inhibitors ; Neoplasm Proteins - biosynthesis ; Neoplasms, Hormone-Dependent - drug therapy ; Neoplasms, Hormone-Dependent - genetics ; Neoplasms, Hormone-Dependent - metabolism ; Neoplasms, Hormone-Dependent - pathology ; Nephrology. Urinary tract diseases ; Nitriles ; Predictive Value of Tests ; prostate carcinoma ; prostate stem cell antigen (PSCA) ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; RNA, Messenger - antagonists & inhibitors ; RNA, Messenger - biosynthesis ; RNA, Messenger - genetics ; RNA, Neoplasm - genetics ; Tosyl Compounds ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2005-12, Vol.65 (4), p.299-305</ispartof><rights>Copyright © 2005 Wiley‐Liss, Inc.</rights><rights>2006 INIST-CNRS</rights><rights>Copyright (c) 2005 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4240-ed524e935332680f702828f551dc06fc8ad59e165915b6709e55e78c57da6003</citedby><cites>FETCH-LOGICAL-c4240-ed524e935332680f702828f551dc06fc8ad59e165915b6709e55e78c57da6003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.20290$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.20290$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17312545$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16015594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhigang, Zhao</creatorcontrib><creatorcontrib>Wenlu, Shen</creatorcontrib><title>Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
Prostate stem cell antigen (PSCA) is a recently identified glycosylphosphatidylinositol (GPI)‐anchored cell surface protein belonging to the Thy‐1/Ly‐6 family of cell surface antigens. Prior data in prostate cancers indicated that PSCA is directly regulated by androgens and PSCA expression increases with high‐tumor grade, advanced stage, extracapsular invasion, and androgen‐independent progression. The effect of complete androgen ablation (CAA) on tumor PSCA mRNA expression has not been elucidated. The purpose of the present study was to investigate the variations in the expression levels of PSCA mRNA before and after CAA, and further evaluate the clinically prognostic value of PSCA in human prostate carcinoma.
MATERIALS AND METHODS
PSCA in situ hybridization (ISH) was performed on the cancerous pretreatment biopsy or transurethral resection of prostate (TURP) tissue of 42 men with primarily organ‐confined prostate cancer before CAA, and on their tumor tissue from radical retropubic prostatectomy after CAA with bicalutamide and goserelin acetate for 3 months prior to undergoing radical prostatectomy. Tumor cytoplasmic staining of PSCA mRNA was evaluated by two independent pathologists and the differences of PSCA mRNA expression levels between the samples before and after CAA were analyzed using the Student's t‐test. Thirty‐six to forty months follow‐up studies after radical retropubic prostatectomy were performed and aimed at assessing the correlation of PSCA mRNA expression level with local recurrences or metastases from the cancer.
RESULTS
The percent of cells positive for PSCA mRNA by ISH labeling declined from 67.3% (0–89%) ± 9.4% before CAA to 33.8% (0–92%) ± 7.7% after CAA (P < 0.001). Before CAA, 40 of 42 cases (95.2%) were positive for PSCA mRNA labeling, however, after CAA the percentage of positive reactivity of PSCA mRNA was decreased to 27 of 40 cases (67.5%), in which none was found with local recurrences or distant metastases after radical prostatectomy on follow‐up. This decline in PSCA mRNA labeling was dependent on the original tumor grade with Gleason score of ≤ 6: 19.3% ± 4.7%, Gleason score of 7: 38.8% ± 7.2%, and a Gleason score of ≥ 8: 73.4% ± 13.8% (P < 0.05, respectively). The rest 13 cases had the increased percentage of cells positive for PSCA mRNA after CAA, in which 3 cases were found with local recurrences and 4 cases with distant metastases from tumor on follow‐up.
CONCLUSIONS
Our data demonstrate that CAA for prostate cancer can suppress PSCA mRNA expression with a tumor grade dependence and the increased expression of PSCA mRNA after CAA may be a clinically adverse predictor for tumor recurrences or distant metastases. Prostate. © 2005 Wiley‐Liss, Inc.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Anilides - therapeutic use</subject><subject>Antigens, Neoplasm</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>complete androgen ablation (CAA)</subject><subject>Follow-Up Studies</subject><subject>GPI-Linked Proteins</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>In Situ Hybridization</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - antagonists & inhibitors</subject><subject>Membrane Glycoproteins - biosynthesis</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - antagonists & inhibitors</subject><subject>Neoplasm Proteins - biosynthesis</subject><subject>Neoplasms, Hormone-Dependent - drug therapy</subject><subject>Neoplasms, Hormone-Dependent - genetics</subject><subject>Neoplasms, Hormone-Dependent - metabolism</subject><subject>Neoplasms, Hormone-Dependent - pathology</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nitriles</subject><subject>Predictive Value of Tests</subject><subject>prostate carcinoma</subject><subject>prostate stem cell antigen (PSCA)</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - pathology</subject><subject>RNA, Messenger - antagonists & inhibitors</subject><subject>RNA, Messenger - biosynthesis</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Neoplasm - genetics</subject><subject>Tosyl Compounds</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90c1O3DAUBWCralWmlE0foMqmFVQKXDuxnSxHoaWV0DAaEEhsLI9zA27zVztR4e1xmIHZdeXNd3yvjwn5ROGYArCT3nX-mAHL4Q2ZUchlDJDyt2QGTEKc0kTukQ_e_wYIHNh7skcFUM7zdEZ80TV9jQNGui1dd4dtpNe1HmzXRn7se4feo4-mEYMOyg_YRAbrOvjBTvxweVnMj6JmtZhH-PAcmMK2je7HRre7qNHO2LZr9EfyrtK1x4PtuU-ufny_Kn7G5xdnv4r5eWxSlkKMJWcp5glPEiYyqCSwjGUV57Q0ICqT6ZLnSAXPKV8LCTlyjjIzXJZaACT75Ovm2rDB3xH9oBrrp9V1i93olchkqCMTAX7bQBNW9Q4r1TvbaPeoKKipYTW9QT03HPDn7a3jusFyR7eVBvBlC7Q3uq6cbo31OycTynjKg6Mb98_W-PifkWq5urh8GR5vMjb8w8NrRrs_SshEcnWzOFOL0-L2-na1VIvkCW-Fovw</recordid><startdate>20051201</startdate><enddate>20051201</enddate><creator>Zhigang, Zhao</creator><creator>Wenlu, Shen</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051201</creationdate><title>Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma</title><author>Zhigang, Zhao ; Wenlu, Shen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4240-ed524e935332680f702828f551dc06fc8ad59e165915b6709e55e78c57da6003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Anilides - therapeutic use</topic><topic>Antigens, Neoplasm</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>complete androgen ablation (CAA)</topic><topic>Follow-Up Studies</topic><topic>GPI-Linked Proteins</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>In Situ Hybridization</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - antagonists & inhibitors</topic><topic>Membrane Glycoproteins - biosynthesis</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - antagonists & inhibitors</topic><topic>Neoplasm Proteins - biosynthesis</topic><topic>Neoplasms, Hormone-Dependent - drug therapy</topic><topic>Neoplasms, Hormone-Dependent - genetics</topic><topic>Neoplasms, Hormone-Dependent - metabolism</topic><topic>Neoplasms, Hormone-Dependent - pathology</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nitriles</topic><topic>Predictive Value of Tests</topic><topic>prostate carcinoma</topic><topic>prostate stem cell antigen (PSCA)</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - pathology</topic><topic>RNA, Messenger - antagonists & inhibitors</topic><topic>RNA, Messenger - biosynthesis</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Neoplasm - genetics</topic><topic>Tosyl Compounds</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhigang, Zhao</creatorcontrib><creatorcontrib>Wenlu, Shen</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhigang, Zhao</au><au>Wenlu, Shen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2005-12-01</date><risdate>2005</risdate><volume>65</volume><issue>4</issue><spage>299</spage><epage>305</epage><pages>299-305</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
Prostate stem cell antigen (PSCA) is a recently identified glycosylphosphatidylinositol (GPI)‐anchored cell surface protein belonging to the Thy‐1/Ly‐6 family of cell surface antigens. Prior data in prostate cancers indicated that PSCA is directly regulated by androgens and PSCA expression increases with high‐tumor grade, advanced stage, extracapsular invasion, and androgen‐independent progression. The effect of complete androgen ablation (CAA) on tumor PSCA mRNA expression has not been elucidated. The purpose of the present study was to investigate the variations in the expression levels of PSCA mRNA before and after CAA, and further evaluate the clinically prognostic value of PSCA in human prostate carcinoma.
MATERIALS AND METHODS
PSCA in situ hybridization (ISH) was performed on the cancerous pretreatment biopsy or transurethral resection of prostate (TURP) tissue of 42 men with primarily organ‐confined prostate cancer before CAA, and on their tumor tissue from radical retropubic prostatectomy after CAA with bicalutamide and goserelin acetate for 3 months prior to undergoing radical prostatectomy. Tumor cytoplasmic staining of PSCA mRNA was evaluated by two independent pathologists and the differences of PSCA mRNA expression levels between the samples before and after CAA were analyzed using the Student's t‐test. Thirty‐six to forty months follow‐up studies after radical retropubic prostatectomy were performed and aimed at assessing the correlation of PSCA mRNA expression level with local recurrences or metastases from the cancer.
RESULTS
The percent of cells positive for PSCA mRNA by ISH labeling declined from 67.3% (0–89%) ± 9.4% before CAA to 33.8% (0–92%) ± 7.7% after CAA (P < 0.001). Before CAA, 40 of 42 cases (95.2%) were positive for PSCA mRNA labeling, however, after CAA the percentage of positive reactivity of PSCA mRNA was decreased to 27 of 40 cases (67.5%), in which none was found with local recurrences or distant metastases after radical prostatectomy on follow‐up. This decline in PSCA mRNA labeling was dependent on the original tumor grade with Gleason score of ≤ 6: 19.3% ± 4.7%, Gleason score of 7: 38.8% ± 7.2%, and a Gleason score of ≥ 8: 73.4% ± 13.8% (P < 0.05, respectively). The rest 13 cases had the increased percentage of cells positive for PSCA mRNA after CAA, in which 3 cases were found with local recurrences and 4 cases with distant metastases from tumor on follow‐up.
CONCLUSIONS
Our data demonstrate that CAA for prostate cancer can suppress PSCA mRNA expression with a tumor grade dependence and the increased expression of PSCA mRNA after CAA may be a clinically adverse predictor for tumor recurrences or distant metastases. Prostate. © 2005 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16015594</pmid><doi>10.1002/pros.20290</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2005-12, Vol.65 (4), p.299-305 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68700086 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Aged, 80 and over Androgen Antagonists - therapeutic use Anilides - therapeutic use Antigens, Neoplasm Biological and medical sciences Biopsy complete androgen ablation (CAA) Follow-Up Studies GPI-Linked Proteins Gynecology. Andrology. Obstetrics Humans In Situ Hybridization Male Medical sciences Membrane Glycoproteins - antagonists & inhibitors Membrane Glycoproteins - biosynthesis Middle Aged Neoplasm Proteins - antagonists & inhibitors Neoplasm Proteins - biosynthesis Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - genetics Neoplasms, Hormone-Dependent - metabolism Neoplasms, Hormone-Dependent - pathology Nephrology. Urinary tract diseases Nitriles Predictive Value of Tests prostate carcinoma prostate stem cell antigen (PSCA) Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology RNA, Messenger - antagonists & inhibitors RNA, Messenger - biosynthesis RNA, Messenger - genetics RNA, Neoplasm - genetics Tosyl Compounds Tumors of the urinary system Urinary tract. Prostate gland |
| title | Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A20%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complete%20androgen%20ablation%20suppresses%20prostate%20stem%20cell%20antigen%20(PSCA)%20mRNA%20expression%20in%20human%20prostate%20carcinoma&rft.jtitle=The%20Prostate&rft.au=Zhigang,%20Zhao&rft.date=2005-12-01&rft.volume=65&rft.issue=4&rft.spage=299&rft.epage=305&rft.pages=299-305&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.20290&rft_dat=%3Cproquest_cross%3E68700086%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68700086&rft_id=info:pmid/16015594&rfr_iscdi=true |